Cue Biopharma, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.83
- 52-Week Range
- $2.83 – $45.50
- Market Cap
- $39.79M
- P/E (TTM)
- —
- EPS (TTM)
- -27.80
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.96
- PEG Ratio
- —
- Return on Equity
- -800.39%
- Return on Assets
- -174.18%
- Gross Margin
- 55.58%
- Operating Margin
- -386.69%
- Profit Margin
- 0.00%
- Current Ratio
- 3.38
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-76.02M
- Revenue Growth
- -93.90%
- Earnings Growth
- —
- Enterprise Value
- $-18.19M
Market Snapshot
About
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively modulate disease-relevant T cells. Headquartered in Boston, Massachusetts, the company's Immuno-STAT platform is designed to harness the body's immune system to fight cancer and autoimmune diseases. Cue Biopharma's lead programs target various cancers including HPV-driven malignancies and other solid tumors. The company's approach aims to deliver more targeted immunotherapy with improved efficacy and reduced side effects compared to traditional treatments.